Arena Pharmaceuticals to Provide Corporate Update

SAN DIEGO, March 06, 2017 (GLOBE NEWSWIRE) -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ), today announced that the Company will provide a corporate update and release its fourth quarter and full-year 2016 financial results on Tuesday, March 14, 2017, after the close of the U.S. financial markets.  The Company will host a conference call and live webcast with the investment community the same day at 4:30 p.m. ET.

Conference Call & Webcast Information When: March 14, 2017, 4:30 p.m. ET Dial-in: (877) 643-7155 (United States) or (914) 495-8552 (International) Conference ID: 80816089

Please join the conference call at least 10 minutes early to register.  You can access the live webcast under the investor relations section of Arena’s website at:  www.arenapharm.com .  A replay of the conference call will be archived under the investor relations section of Arena’s website for 30 days shortly after the call.

About Arena Pharmaceuticals Arena Pharmaceuticals is a biopharmaceutical company focused on developing novel, small molecule drugs across multiple therapeutic areas. Arena is focused on three primary proprietary investigational clinical programs : etrasimod (APD334) in Phase 2 evaluation for multiple autoimmune conditions, ralinepag (APD811) in Phase 2 evaluation for pulmonary arterial hypertension (PAH), and APD371 entering Phase 2 evaluation for the treatment of pain associated with Crohn's disease. In addition, Arena has collaborations with the following pharmaceutical companies: Eisai Co., Ltd. and Eisai Inc. (commercial stage), Axovant Sciences (Phase 2 candidate), and Boehringer Ingelheim International GmbH (preclinical candidate).

Forward-Looking Statements Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements Arena’s focus, primary programs and collaborations. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena’s expectations. Factors that could cause actual results to differ materially from the forward-looking statements include those disclosed in Arena’s filings with the Securities and Exchange Commission. These forward-looking statements represent Arena’s judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contact: Kevin R. Lind, Chief Financial Officer klind@arenapharm.com 858.210.3636